OBJECTIVE: Cancer-testis (CT) genes are considered promising candidates for immunotherapeutic approaches. The aim of this study was to investigate which CT genes should be targeted in immunotherapy for brain tumors. METHODS: We investigated the expression of 6 CT genes (MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85) using reverse-transcription polymerase chain reaction in 26 meningiomas and 32 other various brain tumor specimens, obtained from the patients during tumor surgery from 2000 to 2005. RESULTS: The most frequently expressed CT genes of meningiomas were MAGE-E1, which were found in 22/26 (85%) meningioma samples, followed by SOX-6 (9/26 or 35%). Glioblastomas were most frequently expressed SOX-6 (6/7 or 86%), MAGE-E1 (5/7 or 71%), followed by SSX-2 (2/7 or 29%) and SCP-1 (1/7 or 14%). However, 4 astrocytomas, 3 anaplastic astrocytomas, and 3 oligodendroglial tumors only expressed MAGE-E1 and SOX-6. Schwannomas also expressed SOX-6 (5/6 or 83%), MAGE-E1 (4/6 or 67%), and SCP-1 (2/6 or 33%). CONCLUSION: The data presented here suggest that MAGE-E1 and SOX-6 genes are expressed in a high percentage of human central nervous system tumors, which implies the CT genes could be the potential targets of immunotherapy for human central nervous system tumors.
OBJECTIVE:Cancer-testis (CT) genes are considered promising candidates for immunotherapeutic approaches. The aim of this study was to investigate which CT genes should be targeted in immunotherapy for brain tumors. METHODS: We investigated the expression of 6 CT genes (MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85) using reverse-transcription polymerase chain reaction in 26 meningiomas and 32 other various brain tumor specimens, obtained from the patients during tumor surgery from 2000 to 2005. RESULTS: The most frequently expressed CT genes of meningiomas were MAGE-E1, which were found in 22/26 (85%) meningioma samples, followed by SOX-6 (9/26 or 35%). Glioblastomas were most frequently expressed SOX-6 (6/7 or 86%), MAGE-E1 (5/7 or 71%), followed by SSX-2 (2/7 or 29%) and SCP-1 (1/7 or 14%). However, 4 astrocytomas, 3 anaplastic astrocytomas, and 3 oligodendroglial tumors only expressed MAGE-E1 and SOX-6. Schwannomas also expressed SOX-6 (5/6 or 83%), MAGE-E1 (4/6 or 67%), and SCP-1 (2/6 or 33%). CONCLUSION: The data presented here suggest that MAGE-E1 and SOX-6 genes are expressed in a high percentage of human central nervous system tumors, which implies the CT genes could be the potential targets of immunotherapy for human central nervous system tumors.
Authors: A O Gure; O Türeci; U Sahin; S Tsang; M J Scanlan; E Jäger; A Knuth; M Pfreundschuh; L J Old; Y T Chen Journal: Int J Cancer Date: 1997-09-17 Impact factor: 7.396
Authors: Y T Chen; M J Scanlan; U Sahin; O Türeci; A O Gure; S Tsang; B Williamson; E Stockert; M Pfreundschuh; L J Old Journal: Proc Natl Acad Sci U S A Date: 1997-03-04 Impact factor: 11.205
Authors: Yao-Tseng Chen; Matthew J Scanlan; Charis A Venditti; Ramon Chua; Gregory Theiler; Brian J Stevenson; Christian Iseli; Ali O Gure; Tom Vasicek; Robert L Strausberg; C Victor Jongeneel; Lloyd J Old; Andrew J G Simpson Journal: Proc Natl Acad Sci U S A Date: 2005-05-19 Impact factor: 11.205
Authors: B Lethé; S Lucas; L Michaux; C De Smet; D Godelaine; A Serrano; E De Plaen; T Boon Journal: Int J Cancer Date: 1998-06-10 Impact factor: 7.396
Authors: O Türeci; U Sahin; I Schobert; M Koslowski; H Scmitt; H J Schild; F Stenner; G Seitz; H G Rammensee; M Pfreundschuh Journal: Cancer Res Date: 1996-10-15 Impact factor: 12.701
Authors: Marcelo Freitas; Suzana Malheiros; João Norberto Stávale; Thais Priscila Biassi; Fernando Tadeu Zamunér; Maria de Souza Begnami; Fernando Augusto Soares; Andre Luíz Vettore Journal: Oncotarget Date: 2013-04